206 related articles for article (PubMed ID: 37462077)
1. DeSUMOylation of chromatin-bound proteins limits the rapid transcriptional reprogramming induced by daunorubicin in acute myeloid leukemias.
Boulanger M; Aqrouq M; Tempé D; Kifagi C; Ristic M; Akl D; Hallal R; Carusi A; Gabellier L; de Toledo M; Sigurdsson JO; Kaoma T; Andrieu-Soler C; Forné T; Soler E; Hicheri Y; Gueret E; Vallar L; Olsen JV; Cartron G; Piechaczyk M; Bossis G
Nucleic Acids Res; 2023 Sep; 51(16):8413-8433. PubMed ID: 37462077
[TBL] [Abstract][Full Text] [Related]
2. Targeted inhibition of ULK1 enhances daunorubicin sensitivity in acute myeloid leukemia.
Qiu L; Zhou G; Cao S
Life Sci; 2020 Feb; 243():117234. PubMed ID: 31887299
[TBL] [Abstract][Full Text] [Related]
3. NOXA-mediated degradation of MCL1 and BCL2L1 causes apoptosis of daunorubicin-treated human acute myeloid leukemia cells.
Chiou JT; Huang NC; Huang CH; Wang LJ; Lee YC; Shi YJ; Chang LS
J Cell Physiol; 2021 Nov; 236(11):7356-7375. PubMed ID: 33982799
[TBL] [Abstract][Full Text] [Related]
4. Curcumin reduces expression of Bcl-2, leading to apoptosis in daunorubicin-insensitive CD34+ acute myeloid leukemia cell lines and primary sorted CD34+ acute myeloid leukemia cells.
Rao J; Xu DR; Zheng FM; Long ZJ; Huang SS; Wu X; Zhou WH; Huang RW; Liu Q
J Transl Med; 2011 May; 9():71. PubMed ID: 21595920
[TBL] [Abstract][Full Text] [Related]
5. Ubiquitin and SUMO conjugation as biomarkers of acute myeloid leukemias response to chemotherapies.
Gâtel P; Brockly F; Reynes C; Pastore M; Hicheri Y; Cartron G; Piechaczyk M; Bossis G
Life Sci Alliance; 2020 Jun; 3(6):. PubMed ID: 32303586
[TBL] [Abstract][Full Text] [Related]
6. Differential sensitivity of acute myeloid leukemia cells to daunorubicin depends on P2X7A versus P2X7B receptor expression.
Pegoraro A; Orioli E; De Marchi E; Salvestrini V; Milani A; Di Virgilio F; Curti A; Adinolfi E
Cell Death Dis; 2020 Oct; 11(10):876. PubMed ID: 33071281
[TBL] [Abstract][Full Text] [Related]
7. Population pharmacokinetics of Daunorubicin in adult patients with acute myeloid leukemia.
Varatharajan S; Panetta JC; Abraham A; Karathedath S; Mohanan E; Lakshmi KM; Arthur N; Srivastava VM; Nemani S; George B; Srivastava A; Mathews V; Balasubramanian P
Cancer Chemother Pharmacol; 2016 Nov; 78(5):1051-1058. PubMed ID: 27738808
[TBL] [Abstract][Full Text] [Related]
8. Daunorubicin-containing CLL1-targeting nanomicelles have anti-leukemia stem cell activity in acute myeloid leukemia.
Lin TY; Zhu Y; Li Y; Zhang H; Ma AH; Long Q; Keck J; Lam KS; Pan CX; Jonas BA
Nanomedicine; 2019 Aug; 20():102004. PubMed ID: 31055076
[TBL] [Abstract][Full Text] [Related]
9. Effect of the protein kinase C inhibitor staurosporine on chemosensitivity to daunorubicin of normal and leukemic fresh myeloid cells.
Laredo J; Huynh A; Muller C; Jaffrézou JP; Bailly JD; Cassar G; Laurent G; Demur C
Blood; 1994 Jul; 84(1):229-37. PubMed ID: 7912555
[TBL] [Abstract][Full Text] [Related]
10. [The Mechanism of Artesunate Combined with Cytarabine and/or Daunorubicin on the Apoptosis of MV4-11 MLL-rearranged Acute Myeloid Leukemia Cell Line].
Li JY; Xiong X; Wang DW; Zhang XY; Huang C; Zou LL; Zheng CF; Chen X; Tu CQ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Dec; 30(6):1724-1729. PubMed ID: 36476895
[TBL] [Abstract][Full Text] [Related]
11. Multidrug-resistant acute leukemia cells are responsive to prolonged exposure of daunorubicin: implications for liposome-encapsulated daunorubicin.
Verdonck LF; Lokhorst HM; Roovers DJ; van Heugten HG
Leuk Res; 1998 Mar; 22(3):249-56. PubMed ID: 9619916
[TBL] [Abstract][Full Text] [Related]
12. AML displays increased CTCF occupancy associated with aberrant gene expression and transcription factor binding.
Mujahed H; Miliara S; Neddermeyer A; Bengtzén S; Nilsson C; Deneberg S; Cordeddu L; Ekwall K; Lennartsson A; Lehmann S
Blood; 2020 Jul; 136(3):339-352. PubMed ID: 32232485
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA-33b regulates sensitivity to daunorubicin in acute myelocytic leukemia by regulating eukaryotic translation initiation factor 5A-2.
Liu Y; Lei P; Qiao H; Sun K; Lu X; Bao F; Yu R; Lian C; Li Y; Chen W; Xue F
J Cell Biochem; 2020 Jan; 121(1):385-393. PubMed ID: 31222822
[TBL] [Abstract][Full Text] [Related]
14. Role of NF-E2 related factor 2 (Nrf2) on chemotherapy resistance in acute myeloid leukemia (AML) and the effect of pharmacological inhibition of Nrf2.
Karathedath S; Rajamani BM; Musheer Aalam SM; Abraham A; Varatharajan S; Krishnamurthy P; Mathews V; Velayudhan SR; Balasubramanian P
PLoS One; 2017; 12(5):e0177227. PubMed ID: 28505160
[TBL] [Abstract][Full Text] [Related]
15. Contribution of CTCF binding to transcriptional activity at the HOXA locus in NPM1-mutant AML cells.
Ghasemi R; Struthers H; Wilson ER; Spencer DH
Leukemia; 2021 Feb; 35(2):404-416. PubMed ID: 32398790
[TBL] [Abstract][Full Text] [Related]
16. Transcriptional Response to Standard AML Drugs Identifies Synergistic Combinations.
More P; Ngaffo JAM; Goedtel-Armbrust U; Hähnel PS; Hartwig UF; Kindler T; Wojnowski L
Int J Mol Sci; 2023 Aug; 24(16):. PubMed ID: 37629110
[TBL] [Abstract][Full Text] [Related]
17. High Doses of Daunorubicin during Induction Therapy of Newly Diagnosed Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis of Prospective Clinical Trials.
Gong Q; Zhou L; Xu S; Li X; Zou Y; Chen J
PLoS One; 2015; 10(5):e0125612. PubMed ID: 25993000
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of multi-functional liposomes containing daunorubicin and emetine for treatment of acute myeloid leukaemia.
Myhren L; Nilssen IM; Nicolas V; Døskeland SO; Barratt G; Herfindal L
Eur J Pharm Biopharm; 2014 Sep; 88(1):186-93. PubMed ID: 24747809
[TBL] [Abstract][Full Text] [Related]
19. Novel SAHA‑bendamustine hybrid NL‑101 in combination with daunorubicin synergistically suppresses acute myeloid leukemia.
Jin J; Li X; Guo W; Li F; Huang J; Huang X; Pan J; Huang S; Ye W; Ling Q; Jin J
Oncol Rep; 2020 Jul; 44(1):273-282. PubMed ID: 32626988
[TBL] [Abstract][Full Text] [Related]
20. Daunorubicin-induced internucleosomal DNA fragmentation in acute myeloid cell lines.
Quillet-Mary A; Mansat V; Duchayne E; Come MG; Allouche M; Bailly JD; Bordier C; Laurent G
Leukemia; 1996 Mar; 10(3):417-25. PubMed ID: 8642856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
